Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus

Sponsor
Tanabe Pharma Corporation
Study ID
NCT02227849
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with GLP-1 analogue in patients with type 2 Diabetes for 52 weeks.

Key Dates

Start date
Aug 31, 2014
Status verified
Dec 2025
Primary completion
Mar 31, 2016
Completion
Mar 31, 2016

Study Design

Enrollment
71 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Canagliflozin (TA-7284) ＋GLP-1 analogue

Primary Outcome Measure

Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events) [ Time Frame: 52 Weeks ]

Related Studies